Therapeutics News and Research

RSS

Key immunological changes that support peanut allergy remission in children discovered

Australian researchers have discovered the key immunological changes that support the remission of peanut allergy in children, paving the way for new, more targeted treatments.

25 May 2022

Study brings precision medicine closer to reality for diffuse large B cell lymphoma

DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets.

25 May 2022

AI model can accurately identify patients at high risk of undiagnosed structural heart disease

A team of clinicians and scientists from Tempus and Geisinger have found that a new artificial intelligence model can accurately identify patients at increased risk of undiagnosed structural heart disease.

25 May 2022

Case Western Reserve signs license agreement to bring groundbreaking AI for helping cancer patients

When Case Western Reserve University research showed that artificial intelligence (AI) could identify which lung cancer patients would benefit from chemotherapy, a national magazine called the finding one of the "10 Most Incredible Medical Breakthroughs of 2018."

25 May 2022

The effectiveness of sotrovimab vs. molnupiravir in preventing severe COVID-19 outcomes in non-hospitalized high-risk COVID-19 adult patients

Researchers compared the efficacy of sotrovimab and molnupiravir in preventing severe COVID-19 outcomes among non-hospitalized and high-risk COVID-19 patients across England.

25 May 2022

The effectiveness of molnupiravir and nirmatrelvir/ritonavir in reducing hospitalization and deaths in non-hospitalized COVID-19 patients

Researchers assessed the effectiveness of two orally administered antiviral medications, nirmatrelvir/ritonavir, and molnupiravir, in decreasing hospitalization and deaths among real-world non-hospitalized COVID-19 patients in Hong Kong.

25 May 2022

Dr. Paul Brooks is CN Bio's New Chief Business Officer

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced the appointment of Dr. Paul Brooks as Chief Business Officer.

From CN Bio 25 May 2022

Gut microbiota linked to immunocompromised people's variable response to SARS-CoV-2 vaccination

In a recent study posted to the Research Square* preprint server, researchers assessed whether disturbances in the gut microbiota weaken the serological response to the coronavirus disease 2019 (COVID-19) vaccine in inflammatory bowel disease (IBD) patients.

25 May 2022

Serological biomarker predicts severe Crohn's disease seven years prior to diagnosis

An international team led by a University of Toronto researcher has found that an antibody detectable in blood predicts severe Crohn's disease and is detectable up to seven years prior to disease diagnosis.

24 May 2022

University of Minnesota receives $66 million to establish new antiviral drug discovery center

The University of Minnesota has received $66 million from the National Institute of Allergy and Infectious Diseases to establish a center to develop antiviral drugs for pandemic-level viruses, including SARS-CoV-2.

23 May 2022

Readiness of the United States to combat known and unknown future infectious pathogens

A new study has focused on the preparedness of the United States to respond to known and unknown future infectious pathogens.

23 May 2022

Tiny shark-derived antibodies broadly neutralize most SARS-CoV-2 variants

Resarchers discuss the ability of shark-derived antibodies to protect against multiple variants of SARS-CoV-2.

23 May 2022

Research provides new insight into how Crimean-Congo hemorrhagic fever virus causes disease

Army scientists determined that the body's own natural immune response contributes to disease severity in mice infected with Crimean-Congo hemorrhagic fever virus (CCHFV), which causes a widespread tick-borne viral infection in humans.

20 May 2022

UNC-Chapel Hill secures $65 million NIH grant for establishing Antiviral Drug Discovery Center

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health awarded the UNC Gillings School of Global Public Health a $65 million grant establishing an Antiviral Drug Discovery Center to develop oral antivirals that can combat pandemic-level viruses like COVID-19.

20 May 2022

Molecular target discovery opens new pathways for developing effective anti-angiogenic cancer therapy

Researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute have identified a new molecular drug target that could result in new cancer drugs with fewer side effects.

20 May 2022

Important methodology for targeting conserved epitopes of SARS-CoV-2 and an immune-focused approach in pan-sarbeco and universal CoV vaccine design

A new study has focused on designing immunogens associated with the conserved region of the spike protein of SARS-CoV-2.

20 May 2022

New funding boost to combat antibiotic resistance

Antibiotics have saved countless lives since they were introduced in the 1940s, curing infections and making procedures like chemotherapy and surgeries safer. But their effectiveness is waning.

19 May 2022

New study reveals the genetic mechanism behind severe staphylococcal infections

A common culprit of skin and respiratory infections, Staphylococcus aureus is highly unpredictable. Between 20 and 30 percent of people carry quiet colonies on their skin and in their nostrils, which seldom cause problems beyond the occasional rash.

19 May 2022

Downregulation of MHC-I surface expression by SARS-CoV-2 accessory proteins

Researchers analyze the mechanisms by which two SARS-CoV-2 accessory proteins, ORF3a and ORF7a, can downregulate the expression of MHC-I.

19 May 2022

Intestinal microbiome may contribute to the pathogenesis of MSI colon cancers, study suggests

Investigators from Rutgers Cancer Institute of New Jersey, New Jersey's only National Cancer Institute- Designated Comprehensive Cancer Center, led a collaborative study to examine the patterns of druggable oncogenic fusions in colon cancer specimens including microsatellite-stable and unstable (MSI) tumors.

19 May 2022

Therapeutics News and Research

Key immunological changes that support peanut allergy remission in children discovered

Study brings precision medicine closer to reality for diffuse large B cell lymphoma

AI model can accurately identify patients at high risk of undiagnosed structural heart disease

Case Western Reserve signs license agreement to bring groundbreaking AI for helping cancer patients

The effectiveness of sotrovimab vs. molnupiravir in preventing severe COVID-19 outcomes in non-hospitalized high-risk COVID-19 adult patients

The effectiveness of molnupiravir and nirmatrelvir/ritonavir in reducing hospitalization and deaths in non-hospitalized COVID-19 patients

Dr. Paul Brooks is CN Bio's New Chief Business Officer

Gut microbiota linked to immunocompromised people's variable response to SARS-CoV-2 vaccination

Serological biomarker predicts severe Crohn's disease seven years prior to diagnosis

University of Minnesota receives $66 million to establish new antiviral drug discovery center

Readiness of the United States to combat known and unknown future infectious pathogens

Tiny shark-derived antibodies broadly neutralize most SARS-CoV-2 variants

Research provides new insight into how Crimean-Congo hemorrhagic fever virus causes disease

UNC-Chapel Hill secures $65 million NIH grant for establishing Antiviral Drug Discovery Center

Molecular target discovery opens new pathways for developing effective anti-angiogenic cancer therapy

Important methodology for targeting conserved epitopes of SARS-CoV-2 and an immune-focused approach in pan-sarbeco and universal CoV vaccine design

New funding boost to combat antibiotic resistance

New study reveals the genetic mechanism behind severe staphylococcal infections

Downregulation of MHC-I surface expression by SARS-CoV-2 accessory proteins

Intestinal microbiome may contribute to the pathogenesis of MSI colon cancers, study suggests

Advancing therapeutic biopolymer development eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News